Physician profile
Shevin Dorodi
NPI 1861408510
$6,720.50
in general payments reported to CMS, 2019-2025
39 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $615 · 2021: $905 · 2022: $904 · 2023: $789 · 2024: $1,603 · 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,741 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,740.59 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,073.15 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $815.13 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $556.13 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $533.78 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $431.87 | 2021-2025 | |
| Lilly USA, LLC | $389.11 | 2019-2025 | Mounjaro |
| Glaxosmithkline, LLC. | $269.27 | 2020-2024 | Shingrix, Arexvy |
| Astellas Pharma US INC | $250.94 | 2019-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $235.39 | 2019-2022 | |
| Corcept Therapeutics | $226.77 | 2024 | Korlym |
| Pfizer INC. | $221.90 | 2019-2024 | |
| Abbott Laboratories | $185.80 | 2022-2024 | Freestyle Libre 3 |
| Abbvie INC. | $176.13 | 2021-2024 | Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $164.64 | 2023-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $132.06 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shevin Dorodi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.